Gyre Therapeutics (GYRE) Return on Equity: 2009-2025
Historic Return on Equity for Gyre Therapeutics (GYRE) over the last 16 years, with Sep 2025 value amounting to 0.08%.
- Gyre Therapeutics' Return on Equity rose 96.00% to 0.08% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.08%, marking a year-over-year increase of 96.00%. This contributed to the annual value of 0.41% for FY2024, which is 347.00% up from last year.
- Latest data reveals that Gyre Therapeutics reported Return on Equity of 0.08% as of Q3 2025, which was up 22.48% from 0.07% recorded in Q2 2025.
- Gyre Therapeutics' 5-year Return on Equity high stood at 14.02% for Q4 2023, and its period low was -2.35% during Q1 2022.
- Moreover, its 3-year median value for Return on Equity was 0.11% (2025), whereas its average is 1.22%.
- In the last 5 years, Gyre Therapeutics' Return on Equity surged by 1,395bps in 2023 and then plummeted by 1,385bps in 2024.
- Gyre Therapeutics' Return on Equity (Quarterly) stood at -1.73% in 2021, then spiked by 179bps to 0.07% in 2022, then skyrocketed by 1,395bps to 14.02% in 2023, then slumped by 1,385bps to 0.17% in 2024, then spiked by 96bps to 0.08% in 2025.
- Its last three reported values are 0.08% in Q3 2025, 0.07% for Q2 2025, and 0.11% during Q1 2025.